BioCentury
ARTICLE | Clinical News

Adcirca tadalafil: Phase III data

June 22, 2009 7:00 AM UTC

Data from the double-blind, international Phase III PHIRST-1 trial in 405 patients showed that once-daily 40 mg Adcirca tadalafil met the primary endpoint of a significant increase in 6MWD vs. placebo...